Inclusion Criteria:
- Participants must have histologically confirmed diagnosis of locally advanced or
metastatic ccRCC.
- For part 1: Participants must have already had at least two different treatment
plans in the past, including immunotherapy and a targeted therapy.
- For part 2: Participants must have had at least one standard treatment plan that
included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the
other).
- Participants must have Eastern Cooperative Oncology Group (ECOG) performance status
of 0 to 1.
Exclusion Criteria:
- Participants with Inability to administer and/or tolerate oral medication without
chewing, breaking, crushing, or otherwise altering the product dosage form.
- For Part 2A: Participants who have received more than 3 prior systemic regimens for
locally advanced or metastatic ccRCC including prior treatment with HIF2a
inhibitors.
- Participants who have hypoxia as defined by a pulse oximeter reading < 92% at rest
or requires intermittent or chronic supplemental oxygen.
- Participants who have received colony-stimulating factors (eg, G-CSF, GM-CSF or
recombinant EPO) within 28 days prior to the first dose of study intervention.
- Other protocol-defined Inclusion/Exclusion criteria apply.
